QR kȏd

Threshold for defining PSMA-positivity prior to 177Lu-PSMA therapy: a comparison of [68Ga]Ga-PSMA-11 and [18F]F-DCFPyL in metastatic prostate cancer

Abstract Background In 2022, the American Food and Drug Administration and the European Medicines Agency approved [177Lu]Lu-PSMA-617 (PLUVICTO™, Novartis AG, Basel, Switzerland) for radionuclide therapy with prostate-specific membrane antigen (PSMA) ligands in metastatic prostate cancer. Theranostic...

Cijeli opis

Spremljeno u:
Glavni autori: Jan Heilinger, Jasmin Weindler, Katrin Sabine Roth, Philipp Krapf, Klaus Schomäcker, Markus Dietlein, Alexander Drzezga, Carsten Kobe
Format: Artigo
Jezik:Inglês
Izdano: SpringerOpen 2023-09-01
Serija:EJNMMI Research
Teme:
Prostate cancer
PSMA
PET
Radionuclide therapy
Theranostics
Quantification
Online pristup:https://doi.org/10.1186/s13550-023-01033-x
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Slični predmeti